絞り込み

16532

広告

Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide.

著者 Jiménez R , Díez F , Navarro S , Canelón C , Revelo C
Exp Oncol.2018 Jun ; 40(2):144-148.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (8view , 0users)

Full Text Sources

Over the last decade, significant advances have been made in the development of therapies for patients with metastatic castration-resistant prostate cancer. Abiraterone and enzalutamide were approved as treatments based on data supporting improved overall survival compared to placebo. Radium-223 became the first approved radiopharmaceutical which decreased skeletal-related events, palliated pain, and showed improved overall survival in symptomatic patients with castration-resistant prostate cancer and bone metastasis only.
PMID: 29949528 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード